APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Diabetic Therapeutic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Diabetic Therapeutic Drugs Market Outlook and Growth Opportunities 2026

Report ID 173984140426 December 2025200 pages

Choose your research edition.

Industry ResearchDiabetic Therapeutic Drugs Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Diabetic Therapeutic Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Diabetic Therapeutic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diabetic Therapeutic Drugs Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Diabetic Therapeutic Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Diabetic Therapeutic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Diabetic Therapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diabetic Therapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diabetic Therapeutic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Diabetic Therapeutic Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Diabetic Therapeutic Drugs market include Arbutus Biopharma, AstraZeneca, Belrose Pharma, Dong-A ST, Eisai, F. Hoffmann-La Roche, Mitsubishi Tanabe Pharma, Novo Nordisk and Perle Biosciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Diabetic Therapeutic Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diabetic Therapeutic Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diabetic Therapeutic Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Diabetic Therapeutic Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Diabetic Therapeutic Drugs Segment by Company

Arbutus Biopharma

AstraZeneca

Belrose Pharma

Dong-A ST

Eisai

F. Hoffmann-La Roche

Mitsubishi Tanabe Pharma

Novo Nordisk

Perle Biosciences

Sun Pharma

Pfizer

Eli Lilly

Merck

Novartis

Sanofi

Takeda Pharmaceuticals

Diabetic Therapeutic Drugs Segment by Type

Insulin Therapies

Non-Insulin Therapies

Diabetic Therapeutic Drugs Segment by Application

Type 1 Diabetes

Type 2 Diabetes

Gestational Diabetes

Diabetic Therapeutic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Diabetic Therapeutic Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Diabetic Therapeutic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Diabetic Therapeutic Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Diabetic Therapeutic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Therapeutic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diabetic Therapeutic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Therapeutic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Diabetic Therapeutic Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diabetic Therapeutic Drugs industry.

Chapter 3: Detailed analysis of Diabetic Therapeutic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Diabetic Therapeutic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Diabetic Therapeutic Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Diabetic Therapeutic Drugs Industry Trends Table 2. Diabetic Therapeutic Drugs Industry Drivers Table 3. Diabetic Therapeutic Drugs Industry Opportunities and Challenges Table 4. Diabetic Therapeutic Drugs Industry Restraints Table 5. Global Diabetic Therapeutic Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Diabetic Therapeutic Drugs Revenue Share by Company (2021-2026) Table 7. Global Diabetic Therapeutic Drugs Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Diabetic Therapeutic Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Diabetic Therapeutic Drugs Average Price (US$/Kg) of Company (2021-2026) Table 10. Global Diabetic Therapeutic Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Diabetic Therapeutic Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Diabetic Therapeutic Drugs Company, Product Type & Application Table 13. Global Diabetic Therapeutic Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Diabetic Therapeutic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Insulin Therapies Table 18. Significant Companies of Non-Insulin Therapies Table 19. Global Diabetic Therapeutic Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Diabetic Therapeutic Drugs Sales Volume by Type (2021-2026) & (Tons) Table 21. Global Diabetic Therapeutic Drugs Sales Volume by Type (2027-2032) & (Tons) Table 22. Global Diabetic Therapeutic Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Diabetic Therapeutic Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Diabetic Therapeutic Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Diabetic Therapeutic Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Diabetic Therapeutic Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Diabetic Therapeutic Drugs Sales Value Share by Type (2021-2026) Table 28. Global Diabetic Therapeutic Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Type 1 Diabetes Table 30. Significant Companies of Type 2 Diabetes Table 31. Significant Companies of Gestational Diabetes Table 32. Global Diabetic Therapeutic Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 33. Global Diabetic Therapeutic Drugs Sales Volume by Application (2021-2026) & (Tons) Table 34. Global Diabetic Therapeutic Drugs Sales Volume by Application (2027-2032) & (Tons) Table 35. Global Diabetic Therapeutic Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Diabetic Therapeutic Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Diabetic Therapeutic Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Diabetic Therapeutic Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Diabetic Therapeutic Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Diabetic Therapeutic Drugs Sales Value Share by Application (2021-2026) Table 41. Global Diabetic Therapeutic Drugs Sales Value Share by Application (2027-2032) Table 42. Global Diabetic Therapeutic Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 43. Global Diabetic Therapeutic Drugs Sales by Region (2021-2026) & (Tons) Table 44. Global Diabetic Therapeutic Drugs Sales Market Share by Region (2021-2026) Table 45. Global Diabetic Therapeutic Drugs Sales by Region (2027-2032) & (Tons) Table 46. Global Diabetic Therapeutic Drugs Sales Market Share by Region (2027-2032) Table 47. Global Diabetic Therapeutic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Diabetic Therapeutic Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Diabetic Therapeutic Drugs Sales Value Share by Region (2021-2026) Table 50. Global Diabetic Therapeutic Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Diabetic Therapeutic Drugs Sales Value Share by Region (2027-2032) Table 52. Global Diabetic Therapeutic Drugs Market Average Price (US$/Kg) by Region (2021-2026) Table 53. Global Diabetic Therapeutic Drugs Market Average Price (US$/Kg) by Region (2027-2032) Table 54. Global Diabetic Therapeutic Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 55. Global Diabetic Therapeutic Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Diabetic Therapeutic Drugs Sales by Country (2021-2026) & (Tons) Table 57. Global Diabetic Therapeutic Drugs Sales Market Share by Country (2021-2026) Table 58. Global Diabetic Therapeutic Drugs Sales by Country (2027-2032) & (Tons) Table 59. Global Diabetic Therapeutic Drugs Sales Market Share by Country (2027-2032) Table 60. Global Diabetic Therapeutic Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Diabetic Therapeutic Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Diabetic Therapeutic Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Diabetic Therapeutic Drugs Sales Value Market Share by Country (2027-2032) Table 64. Arbutus Biopharma Company Information Table 65. Arbutus Biopharma Business Overview Table 66. Arbutus Biopharma Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 67. Arbutus Biopharma Diabetic Therapeutic Drugs Product Portfolio Table 68. Arbutus Biopharma Recent Development Table 69. AstraZeneca Company Information Table 70. AstraZeneca Business Overview Table 71. AstraZeneca Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 72. AstraZeneca Diabetic Therapeutic Drugs Product Portfolio Table 73. AstraZeneca Recent Development Table 74. Belrose Pharma Company Information Table 75. Belrose Pharma Business Overview Table 76. Belrose Pharma Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 77. Belrose Pharma Diabetic Therapeutic Drugs Product Portfolio Table 78. Belrose Pharma Recent Development Table 79. Dong-A ST Company Information Table 80. Dong-A ST Business Overview Table 81. Dong-A ST Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 82. Dong-A ST Diabetic Therapeutic Drugs Product Portfolio Table 83. Dong-A ST Recent Development Table 84. Eisai Company Information Table 85. Eisai Business Overview Table 86. Eisai Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 87. Eisai Diabetic Therapeutic Drugs Product Portfolio Table 88. Eisai Recent Development Table 89. F. Hoffmann-La Roche Company Information Table 90. F. Hoffmann-La Roche Business Overview Table 91. F. Hoffmann-La Roche Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 92. F. Hoffmann-La Roche Diabetic Therapeutic Drugs Product Portfolio Table 93. F. Hoffmann-La Roche Recent Development Table 94. Mitsubishi Tanabe Pharma Company Information Table 95. Mitsubishi Tanabe Pharma Business Overview Table 96. Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 97. Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Product Portfolio Table 98. Mitsubishi Tanabe Pharma Recent Development Table 99. Novo Nordisk Company Information Table 100. Novo Nordisk Business Overview Table 101. Novo Nordisk Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 102. Novo Nordisk Diabetic Therapeutic Drugs Product Portfolio Table 103. Novo Nordisk Recent Development Table 104. Perle Biosciences Company Information Table 105. Perle Biosciences Business Overview Table 106. Perle Biosciences Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 107. Perle Biosciences Diabetic Therapeutic Drugs Product Portfolio Table 108. Perle Biosciences Recent Development Table 109. Sun Pharma Company Information Table 110. Sun Pharma Business Overview Table 111. Sun Pharma Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 112. Sun Pharma Diabetic Therapeutic Drugs Product Portfolio Table 113. Sun Pharma Recent Development Table 114. Pfizer Company Information Table 115. Pfizer Business Overview Table 116. Pfizer Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 117. Pfizer Diabetic Therapeutic Drugs Product Portfolio Table 118. Pfizer Recent Development Table 119. Eli Lilly Company Information Table 120. Eli Lilly Business Overview Table 121. Eli Lilly Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 122. Eli Lilly Diabetic Therapeutic Drugs Product Portfolio Table 123. Eli Lilly Recent Development Table 124. Merck Company Information Table 125. Merck Business Overview Table 126. Merck Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 127. Merck Diabetic Therapeutic Drugs Product Portfolio Table 128. Merck Recent Development Table 129. Novartis Company Information Table 130. Novartis Business Overview Table 131. Novartis Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 132. Novartis Diabetic Therapeutic Drugs Product Portfolio Table 133. Novartis Recent Development Table 134. Sanofi Company Information Table 135. Sanofi Business Overview Table 136. Sanofi Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 137. Sanofi Diabetic Therapeutic Drugs Product Portfolio Table 138. Sanofi Recent Development Table 139. Takeda Pharmaceuticals Company Information Table 140. Takeda Pharmaceuticals Business Overview Table 141. Takeda Pharmaceuticals Diabetic Therapeutic Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 142. Takeda Pharmaceuticals Diabetic Therapeutic Drugs Product Portfolio Table 143. Takeda Pharmaceuticals Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Diabetic Therapeutic Drugs Distributors List Table 147. Diabetic Therapeutic Drugs Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Diabetic Therapeutic Drugs Product Image Figure 2. Global Diabetic Therapeutic Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diabetic Therapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Diabetic Therapeutic Drugs Sales (2021-2032) & (Tons) Figure 5. Global Diabetic Therapeutic Drugs Sales Average Price (US$/Kg) & (2021-2032) Figure 6. Global Diabetic Therapeutic Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Insulin Therapies Image Figure 10. Non-Insulin Therapies Image Figure 11. Global Diabetic Therapeutic Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Diabetic Therapeutic Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Diabetic Therapeutic Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Diabetic Therapeutic Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Diabetic Therapeutic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Diabetic Therapeutic Drugs Sales Value Share by Type (2021-2032) Figure 17. Type 1 Diabetes Image Figure 18. Type 2 Diabetes Image Figure 19. Gestational Diabetes Image Figure 20. Global Diabetic Therapeutic Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 21. Global Diabetic Therapeutic Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Diabetic Therapeutic Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Diabetic Therapeutic Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Diabetic Therapeutic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Diabetic Therapeutic Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Diabetic Therapeutic Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 27. Global Diabetic Therapeutic Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Diabetic Therapeutic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Diabetic Therapeutic Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Diabetic Therapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Diabetic Therapeutic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Diabetic Therapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Diabetic Therapeutic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Diabetic Therapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Diabetic Therapeutic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Diabetic Therapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Diabetic Therapeutic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Diabetic Therapeutic Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Diabetic Therapeutic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Diabetic Therapeutic Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Diabetic Therapeutic Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin Therapies
  • Non-Insulin Therapies
Applications
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
Companies covered
  • Arbutus Biopharma
  • AstraZeneca
  • Belrose Pharma
  • Dong-A ST
  • Eisai
  • F. Hoffmann-La Roche
  • Mitsubishi Tanabe Pharma
  • Novo Nordisk
  • Perle Biosciences
  • Sun Pharma
  • Pfizer
  • Eli Lilly
  • Merck
  • Novartis
  • Sanofi
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Diabetic Therapeutic Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Diabetic Therapeutic Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Diabetic Therapeutic Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Diabetic Therapeutic Drugs Market Dynamics
  1. 2.1 Diabetic Therapeutic Drugs Industry Trends
  2. 2.2 Diabetic Therapeutic Drugs Industry Drivers
  3. 2.3 Diabetic Therapeutic Drugs Industry Opportunities and Challenges
  4. 2.4 Diabetic Therapeutic Drugs Industry Restraints
3 Diabetic Therapeutic Drugs Market by Company
  1. 3.1 Global Diabetic Therapeutic Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Diabetic Therapeutic Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Diabetic Therapeutic Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Diabetic Therapeutic Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Diabetic Therapeutic Drugs Company Ranking (2024-2026)
  6. 3.6 Global Diabetic Therapeutic Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Diabetic Therapeutic Drugs Company Product Type and Application
  8. 3.8 Global Diabetic Therapeutic Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Diabetic Therapeutic Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Diabetic Therapeutic Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Diabetic Therapeutic Drugs Market by Type
  1. 4.1 Diabetic Therapeutic Drugs Type Introduction
  2. 4.1.1 Insulin Therapies
  3. 4.1.2 Non-Insulin Therapies
  4. 4.2 Global Diabetic Therapeutic Drugs Sales Volume by Type
  5. 4.2.1 Global Diabetic Therapeutic Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Diabetic Therapeutic Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Diabetic Therapeutic Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Diabetic Therapeutic Drugs Sales Value by Type
  9. 4.3.1 Global Diabetic Therapeutic Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Diabetic Therapeutic Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Diabetic Therapeutic Drugs Sales Value Share by Type (2021-2032)
5 Diabetic Therapeutic Drugs Market by Application
  1. 5.1 Diabetic Therapeutic Drugs Application Introduction
  2. 5.1.1 Type 1 Diabetes
  3. 5.1.2 Type 2 Diabetes
  4. 5.1.3 Gestational Diabetes
  5. 5.2 Global Diabetic Therapeutic Drugs Sales Volume by Application
  6. 5.2.1 Global Diabetic Therapeutic Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Diabetic Therapeutic Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Diabetic Therapeutic Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Diabetic Therapeutic Drugs Sales Value by Application
  10. 5.3.1 Global Diabetic Therapeutic Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Diabetic Therapeutic Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Diabetic Therapeutic Drugs Sales Value Share by Application (2021-2032)
6 Diabetic Therapeutic Drugs Regional Sales and Value Analysis
  1. 6.1 Global Diabetic Therapeutic Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diabetic Therapeutic Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Diabetic Therapeutic Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Diabetic Therapeutic Drugs Sales by Region (2027-2032)
  5. 6.3 Global Diabetic Therapeutic Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Diabetic Therapeutic Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Diabetic Therapeutic Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Diabetic Therapeutic Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Diabetic Therapeutic Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Diabetic Therapeutic Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Diabetic Therapeutic Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Diabetic Therapeutic Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Diabetic Therapeutic Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Diabetic Therapeutic Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Diabetic Therapeutic Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Diabetic Therapeutic Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Diabetic Therapeutic Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Diabetic Therapeutic Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Diabetic Therapeutic Drugs Sales Value Share by Country, 2025 VS 2032
7 Diabetic Therapeutic Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Diabetic Therapeutic Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Diabetic Therapeutic Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Diabetic Therapeutic Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Diabetic Therapeutic Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Diabetic Therapeutic Drugs Sales by Country (2027-2032)
  6. 7.4 Global Diabetic Therapeutic Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Diabetic Therapeutic Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Diabetic Therapeutic Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Diabetic Therapeutic Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Diabetic Therapeutic Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Diabetic Therapeutic Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Arbutus Biopharma
  2. 8.1.1 Arbutus Biopharma Company Information
  3. 8.1.2 Arbutus Biopharma Business Overview
  4. 8.1.3 Arbutus Biopharma Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Arbutus Biopharma Diabetic Therapeutic Drugs Product Portfolio
  6. 8.1.5 Arbutus Biopharma Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Diabetic Therapeutic Drugs Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Belrose Pharma
  14. 8.3.1 Belrose Pharma Company Information
  15. 8.3.2 Belrose Pharma Business Overview
  16. 8.3.3 Belrose Pharma Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Belrose Pharma Diabetic Therapeutic Drugs Product Portfolio
  18. 8.3.5 Belrose Pharma Recent Developments
  19. 8.4 Dong-A ST
  20. 8.4.1 Dong-A ST Company Information
  21. 8.4.2 Dong-A ST Business Overview
  22. 8.4.3 Dong-A ST Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dong-A ST Diabetic Therapeutic Drugs Product Portfolio
  24. 8.4.5 Dong-A ST Recent Developments
  25. 8.5 Eisai
  26. 8.5.1 Eisai Company Information
  27. 8.5.2 Eisai Business Overview
  28. 8.5.3 Eisai Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eisai Diabetic Therapeutic Drugs Product Portfolio
  30. 8.5.5 Eisai Recent Developments
  31. 8.6 F. Hoffmann-La Roche
  32. 8.6.1 F. Hoffmann-La Roche Company Information
  33. 8.6.2 F. Hoffmann-La Roche Business Overview
  34. 8.6.3 F. Hoffmann-La Roche Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 F. Hoffmann-La Roche Diabetic Therapeutic Drugs Product Portfolio
  36. 8.6.5 F. Hoffmann-La Roche Recent Developments
  37. 8.7 Mitsubishi Tanabe Pharma
  38. 8.7.1 Mitsubishi Tanabe Pharma Company Information
  39. 8.7.2 Mitsubishi Tanabe Pharma Business Overview
  40. 8.7.3 Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Product Portfolio
  42. 8.7.5 Mitsubishi Tanabe Pharma Recent Developments
  43. 8.8 Novo Nordisk
  44. 8.8.1 Novo Nordisk Company Information
  45. 8.8.2 Novo Nordisk Business Overview
  46. 8.8.3 Novo Nordisk Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Novo Nordisk Diabetic Therapeutic Drugs Product Portfolio
  48. 8.8.5 Novo Nordisk Recent Developments
  49. 8.9 Perle Biosciences
  50. 8.9.1 Perle Biosciences Company Information
  51. 8.9.2 Perle Biosciences Business Overview
  52. 8.9.3 Perle Biosciences Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Perle Biosciences Diabetic Therapeutic Drugs Product Portfolio
  54. 8.9.5 Perle Biosciences Recent Developments
  55. 8.10 Sun Pharma
  56. 8.10.1 Sun Pharma Company Information
  57. 8.10.2 Sun Pharma Business Overview
  58. 8.10.3 Sun Pharma Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sun Pharma Diabetic Therapeutic Drugs Product Portfolio
  60. 8.10.5 Sun Pharma Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Diabetic Therapeutic Drugs Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Eli Lilly
  68. 8.12.1 Eli Lilly Company Information
  69. 8.12.2 Eli Lilly Business Overview
  70. 8.12.3 Eli Lilly Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Eli Lilly Diabetic Therapeutic Drugs Product Portfolio
  72. 8.12.5 Eli Lilly Recent Developments
  73. 8.13 Merck
  74. 8.13.1 Merck Company Information
  75. 8.13.2 Merck Business Overview
  76. 8.13.3 Merck Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Merck Diabetic Therapeutic Drugs Product Portfolio
  78. 8.13.5 Merck Recent Developments
  79. 8.14 Novartis
  80. 8.14.1 Novartis Company Information
  81. 8.14.2 Novartis Business Overview
  82. 8.14.3 Novartis Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Novartis Diabetic Therapeutic Drugs Product Portfolio
  84. 8.14.5 Novartis Recent Developments
  85. 8.15 Sanofi
  86. 8.15.1 Sanofi Company Information
  87. 8.15.2 Sanofi Business Overview
  88. 8.15.3 Sanofi Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Sanofi Diabetic Therapeutic Drugs Product Portfolio
  90. 8.15.5 Sanofi Recent Developments
  91. 8.16 Takeda Pharmaceuticals
  92. 8.16.1 Takeda Pharmaceuticals Company Information
  93. 8.16.2 Takeda Pharmaceuticals Business Overview
  94. 8.16.3 Takeda Pharmaceuticals Diabetic Therapeutic Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Takeda Pharmaceuticals Diabetic Therapeutic Drugs Product Portfolio
  96. 8.16.5 Takeda Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Diabetic Therapeutic Drugs Value Chain Analysis
  2. 9.1.1 Diabetic Therapeutic Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Diabetic Therapeutic Drugs Sales Mode & Process
  6. 9.2 Diabetic Therapeutic Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Diabetic Therapeutic Drugs Distributors
  9. 9.2.3 Diabetic Therapeutic Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst